within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FC01_Daratumumab;

model Daratumumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FC01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FC01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Daratumumab is a human IgG1κ monoclonal antibody that targets CD38, a glycoprotein highly expressed on myeloma cells. It is used for the treatment of multiple myeloma, either as monotherapy or in combination with other agents. Daratumumab is approved for clinical use and is widely used in current therapeutic regimens for relapsed/refractory multiple myeloma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients (both sexes, median age ~64) with relapsed/refractory multiple myeloma administered daratumumab 16 mg/kg intravenously, data from clinical trials population PK models.</p><h4>References</h4><ol><li><p>Kim, K, &amp; Phelps, MA (2023). Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. <i>Clinical pharmacokinetics</i> 62(6) 789–806. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01240-8&quot;>10.1007/s40262-023-01240-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37129750/&quot;>https://pubmed.ncbi.nlm.nih.gov/37129750</a></p></li><li><p>Mateos, MV, et al., &amp; Usmani, SZ (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>The Lancet. Haematology</i> 7(5) e370–e380. DOI:<a href=&quot;https://doi.org/10.1016/S2352-3026(20)30070-3&quot;>10.1016/S2352-3026(20)30070-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32213342/&quot;>https://pubmed.ncbi.nlm.nih.gov/32213342</a></p></li><li><p>Clemens, PL, et al., &amp; Xu, XS (2017). Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. <i>Clinical pharmacokinetics</i> 56(8) 915–924. DOI:<a href=&quot;https://doi.org/10.1007/s40262-016-0477-1&quot;>10.1007/s40262-016-0477-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27896689/&quot;>https://pubmed.ncbi.nlm.nih.gov/27896689</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Daratumumab;
